Changes in Sleep Pattern During the COVID-19 Lockdown in Patients With Narcolepsy, Idiopathic Hypersomnia, and Restless Legs Syndrome.


Journal

Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060

Informations de publication

Date de publication:
04 10 2022
Historique:
received: 13 01 2022
accepted: 16 05 2022
pubmed: 3 8 2022
medline: 6 10 2022
entrez: 2 8 2022
Statut: ppublish

Résumé

To explore the first coronavirus disease 2019 (COVID-19) lockdown effect on sleep symptoms in patients with narcolepsy, idiopathic hypersomnia (IH), and restless legs syndrome (RLS). Between March and May 2020, a sample of adult patients regularly followed up in a Reference Hospital Sleep Unit (299 with narcolepsy, 260 with IH, and 254 with RLS) was offered an online survey assessing their sleep-wake habits, daily activities, medication intake, and validated scales: International RLS Study Group questionnaire, Narcolepsy Severity Scale (NSS), IH Severity Scale (IHSS), Epworth Sleepiness Scale (ESS), Insomnia Severity Index, Beck Depression Inventory-II, and European Quality of Life (QoL) scale. The survey was proposed once, and the questions were answered for the prelockdown (recall of the month before the confinement) and the lockdown (time of study) periods. Overall, 331 patients completed the survey (response rate 40.7%): 102 with narcolepsy, 81 with IH, and 148 with RLS. All patients reported later bedtimes, with reduced differences for time in bed (TIB) and total sleep time (TST) over 24 hours between weekdays and weekends. Patients with narcolepsy spent more TIB and increased TST overnight, with more daytime napping. They had more awakenings, higher ESS scores, lower QoL, and no NSS changes. Patients with IH also increased their TIB, TST overnight and 24 hours on weekdays. Nocturnal sleep latency and the number of awakenings increased but with no change in ESS, QoL, and IHSS scores. Patients with RLS reported longer nocturnal sleep latency, more awakenings, more naps, decreased TIB, and TST overnight. RLS severity increased while QoL decreased. A significant portion of patients reported disease worsening during the lockdown (narcolepsy: 39.4%, IH: 43.6%, and RLS: 32.8%), and some patients stopped or lowered their medication (narcolepsy: 22.5%, IH: 28%, and RLS: 9.5%). During the lockdown, all patients reported later bedtimes; those with narcolepsy and IH extended their sleep duration unlike patients with RLS. These changes were often associated with negative consequences on QoL. In the current context of recurrent COVID-19 waves, the recent development of teleconsultations should enable physicians to monitor patients with chronic sleep disorders more closely and to recommend optimized sleep schedules and duration, in order to prevent psychological problems and improve their QoL.

Sections du résumé

BACKGROUND AND OBJECTIVES
To explore the first coronavirus disease 2019 (COVID-19) lockdown effect on sleep symptoms in patients with narcolepsy, idiopathic hypersomnia (IH), and restless legs syndrome (RLS).
METHODS
Between March and May 2020, a sample of adult patients regularly followed up in a Reference Hospital Sleep Unit (299 with narcolepsy, 260 with IH, and 254 with RLS) was offered an online survey assessing their sleep-wake habits, daily activities, medication intake, and validated scales: International RLS Study Group questionnaire, Narcolepsy Severity Scale (NSS), IH Severity Scale (IHSS), Epworth Sleepiness Scale (ESS), Insomnia Severity Index, Beck Depression Inventory-II, and European Quality of Life (QoL) scale. The survey was proposed once, and the questions were answered for the prelockdown (recall of the month before the confinement) and the lockdown (time of study) periods.
RESULTS
Overall, 331 patients completed the survey (response rate 40.7%): 102 with narcolepsy, 81 with IH, and 148 with RLS. All patients reported later bedtimes, with reduced differences for time in bed (TIB) and total sleep time (TST) over 24 hours between weekdays and weekends. Patients with narcolepsy spent more TIB and increased TST overnight, with more daytime napping. They had more awakenings, higher ESS scores, lower QoL, and no NSS changes. Patients with IH also increased their TIB, TST overnight and 24 hours on weekdays. Nocturnal sleep latency and the number of awakenings increased but with no change in ESS, QoL, and IHSS scores. Patients with RLS reported longer nocturnal sleep latency, more awakenings, more naps, decreased TIB, and TST overnight. RLS severity increased while QoL decreased. A significant portion of patients reported disease worsening during the lockdown (narcolepsy: 39.4%, IH: 43.6%, and RLS: 32.8%), and some patients stopped or lowered their medication (narcolepsy: 22.5%, IH: 28%, and RLS: 9.5%).
DISCUSSION
During the lockdown, all patients reported later bedtimes; those with narcolepsy and IH extended their sleep duration unlike patients with RLS. These changes were often associated with negative consequences on QoL. In the current context of recurrent COVID-19 waves, the recent development of teleconsultations should enable physicians to monitor patients with chronic sleep disorders more closely and to recommend optimized sleep schedules and duration, in order to prevent psychological problems and improve their QoL.

Identifiants

pubmed: 35918167
pii: WNL.0000000000200907
doi: 10.1212/WNL.0000000000200907
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1475-e1485

Informations de copyright

© 2022 American Academy of Neurology.

Auteurs

Lucie Barateau (L)

From the Sleep-Wake Disorders Unit (L.B., S.C., A.L.R., C. Denis, Q.L., C. Dhalluin, R.L., Y.D.), Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier; National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome (L.B., S.C., A.L.R., R.L., Y.D.), Montpellier; and Institute for Neurosciences of Montpellier (L.B., R.L., I.J., S.B., Y.D.), University of Montpellier, INSERM, France. l-barateau@chu-montpellier.fr.

Sofiene Chenini (S)

From the Sleep-Wake Disorders Unit (L.B., S.C., A.L.R., C. Denis, Q.L., C. Dhalluin, R.L., Y.D.), Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier; National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome (L.B., S.C., A.L.R., R.L., Y.D.), Montpellier; and Institute for Neurosciences of Montpellier (L.B., R.L., I.J., S.B., Y.D.), University of Montpellier, INSERM, France.

Anna Laura Rassu (AL)

From the Sleep-Wake Disorders Unit (L.B., S.C., A.L.R., C. Denis, Q.L., C. Dhalluin, R.L., Y.D.), Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier; National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome (L.B., S.C., A.L.R., R.L., Y.D.), Montpellier; and Institute for Neurosciences of Montpellier (L.B., R.L., I.J., S.B., Y.D.), University of Montpellier, INSERM, France.

Claire Denis (C)

From the Sleep-Wake Disorders Unit (L.B., S.C., A.L.R., C. Denis, Q.L., C. Dhalluin, R.L., Y.D.), Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier; National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome (L.B., S.C., A.L.R., R.L., Y.D.), Montpellier; and Institute for Neurosciences of Montpellier (L.B., R.L., I.J., S.B., Y.D.), University of Montpellier, INSERM, France.

Quentin Lorber (Q)

From the Sleep-Wake Disorders Unit (L.B., S.C., A.L.R., C. Denis, Q.L., C. Dhalluin, R.L., Y.D.), Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier; National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome (L.B., S.C., A.L.R., R.L., Y.D.), Montpellier; and Institute for Neurosciences of Montpellier (L.B., R.L., I.J., S.B., Y.D.), University of Montpellier, INSERM, France.

Cloé Dhalluin (C)

From the Sleep-Wake Disorders Unit (L.B., S.C., A.L.R., C. Denis, Q.L., C. Dhalluin, R.L., Y.D.), Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier; National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome (L.B., S.C., A.L.R., R.L., Y.D.), Montpellier; and Institute for Neurosciences of Montpellier (L.B., R.L., I.J., S.B., Y.D.), University of Montpellier, INSERM, France.

Regis Lopez (R)

From the Sleep-Wake Disorders Unit (L.B., S.C., A.L.R., C. Denis, Q.L., C. Dhalluin, R.L., Y.D.), Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier; National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome (L.B., S.C., A.L.R., R.L., Y.D.), Montpellier; and Institute for Neurosciences of Montpellier (L.B., R.L., I.J., S.B., Y.D.), University of Montpellier, INSERM, France.

Isabelle Jaussent (I)

From the Sleep-Wake Disorders Unit (L.B., S.C., A.L.R., C. Denis, Q.L., C. Dhalluin, R.L., Y.D.), Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier; National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome (L.B., S.C., A.L.R., R.L., Y.D.), Montpellier; and Institute for Neurosciences of Montpellier (L.B., R.L., I.J., S.B., Y.D.), University of Montpellier, INSERM, France.

Séverine Beziat (S)

From the Sleep-Wake Disorders Unit (L.B., S.C., A.L.R., C. Denis, Q.L., C. Dhalluin, R.L., Y.D.), Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier; National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome (L.B., S.C., A.L.R., R.L., Y.D.), Montpellier; and Institute for Neurosciences of Montpellier (L.B., R.L., I.J., S.B., Y.D.), University of Montpellier, INSERM, France.

Yves Dauvilliers (Y)

From the Sleep-Wake Disorders Unit (L.B., S.C., A.L.R., C. Denis, Q.L., C. Dhalluin, R.L., Y.D.), Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier; National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome (L.B., S.C., A.L.R., R.L., Y.D.), Montpellier; and Institute for Neurosciences of Montpellier (L.B., R.L., I.J., S.B., Y.D.), University of Montpellier, INSERM, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH